FIRST-NEC (GFPC 01-2022) - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506590-35-00

Acronym

ET23-132

Enrollment

Registered

2024-03-14

Start date

2024-06-13

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large-Cell NeuroEndocrine Carcinoma of the lung, locally advanced (Stage III) not eligible for loco-regional therapy or metastatic (Stage IV) in first line treatment

Brief summary

Progression-Free Rate at 12 months

Interventions

DRUGCARBOPLATIN

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGETOPOSIDE

DRUGCISPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Rate at 12 months	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026